475830 - Orum Therapeutics, Inc.

475830 Summary

Biopharma

Stock Price & Overview

₩55,900 +1,400 (+2.57%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩55,900 ≈ US$40 · Market cap ₩1.2tn (≈ $867m)

475830 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Revenue	0.0	20.9	135.4	0.1
Selling, General & Administrative	16.1	12.2	21.1	10.6
Operating Income	-51.8	-8.3	95.6	-43.6
Finance Income	4.8	11.2	1.8	1.5
Finance Costs	2.9	8.2	29.7	20.9
Pretax Income	-44.2	-5.3	67.9	-63.1
Income Tax Expense	-2.2	0.4	-0.3	0.2
Net Income	-42.0	-5.7	68.2	-63.3
Total Comprehensive Income	-42.2	-3.8	68.4	-63.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Assets	169.3	153.8	161.8	21.3
Current Assets	134.4	122.5	127.4	12.7
Cash & Cash Equivalents	4.1	19.7	126.7	11.3
Trade Receivables	0.0	0.0	0.0	0.0
Non-current Assets	35.0	31.3	34.3	8.6
Property, Plant & Equipment	2.8	3.2	2.6	3.7
Total Liabilities	38.4	32.1	218.0	148.7
Current Liabilities	15.6	31.9	194.5	147.1
Non-current Liabilities	22.8	0.2	23.4	1.7
Total Equity	130.9	121.8	-56.2	-127.5
Share Capital	2.1	1.8	0.5	0.1
Retained Earnings	18.2	-69.8	-64.1	-132.3

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Cash from Operating Activities	-36.0	-11.3	94.2	-41.1
Cash from Investing Activities	-28.3	-98.5	-2.4	26.7
Cash from Financing Activities	48.7	-0.8	23.6	-1.4
Net Change in Cash	-15.6	-110.6	115.4	-15.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	—
Selling, General & Administrative	4.6	4.3	4.3	4.1	3.8	4.0	—
Operating Income	-15.4	-18.1	-18.3	-13.9	-10.0	-9.6	—
Finance Income	93.9	3.9	0.9	0.6	2.3	1.1	—
Finance Costs	15.2	1.1	0.8	0.3	1.3	0.6	—
Pretax Income	63.4	-15.3	-18.2	-13.6	-3.8	-8.6	—
Income Tax Expense	0.0	0.0	-2.2	0.0	0.0	0.0	—
Net Income	63.4	-15.3	-16.0	-13.6	-3.8	-8.6	—
Total Comprehensive Income	63.8	-14.1	-15.5	-13.1	-5.5	-8.1	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Total Assets	292.0	312.8	169.3	182.3	185.7	191.5	153.8
Current Assets	256.1	276.9	134.4	149.7	153.6	160.7	122.5
Cash & Cash Equivalents	113.6	113.1	4.1	15.5	5.8	7.4	19.7
Trade Receivables	0.0	—	0.0	0.0	0.0	0.0	0.0
Non-current Assets	35.9	36.0	35.0	32.6	32.1	30.8	31.3
Property, Plant & Equipment	2.6	2.7	2.8	2.7	2.7	3.0	3.2
Total Liabilities	106.0	193.2	38.4	37.1	28.5	29.7	32.1
Current Liabilities	82.0	169.4	15.6	14.5	6.4	5.7	31.9
Non-current Liabilities	24.0	23.9	22.8	22.6	22.1	24.1	0.2
Total Equity	186.0	119.6	130.9	145.2	157.2	161.8	121.8
Share Capital	2.2	2.1	2.1	2.1	2.1	2.1	1.8
Retained Earnings	66.3	2.9	18.2	34.2	-82.2	-78.4	-69.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Cash from Operating Activities	-19.0	-15.3	-11.6	-6.3	-10.8	-7.3	—
Cash from Investing Activities	18.1	-22.2	-0.0	15.6	8.5	-52.4	—
Cash from Financing Activities	1.4	146.6	0.2	0.4	0.6	47.5	—
Net Change in Cash	0.5	109.1	-11.4	9.7	-1.8	-12.2	—

Consolidated (CFS), from DART. 4 fiscal years and 7 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

475830 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	0.0	-99.9%	-32.3%	—	—
Operating income	-51.8	—	—	—	—
Net income	-42.0	—	—	—	—
EPS	₩-1,932	—	—	—	—
Operating cash flow	-36.0	—	—	—	—
Shareholders' equity	130.9	+7.5%	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

475830 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022
Operating margin	-219,651.4%	-39.9%	70.6%	-57,492.6%
Net margin	-178,105.4%	-27.5%	50.4%	-83,402.6%
Return on equity	-33.2%	-17.5%	—	—
Return on assets	-26.0%	-3.6%	74.5%	-297.5%
Operating cash flow / revenue	-152,725.9%	-54.0%	69.6%	-54,125.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 475830

Symbol	Last Price
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
195940HK inno.N Corporation	₩42,050 +0.7%
003090Daewoong Co., Ltd.	₩16,860 -2.0%
086450Dong Kook Pharmaceutical Co., Ltd.	₩21,600 -0.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.